BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29845742)

  • 1. Selective CXCR4
    Díaz R; Pallarès V; Cano-Garrido O; Serna N; Sánchez-García L; Falgàs A; Pesarrodona M; Unzueta U; Sánchez-Chardi A; Sánchez JM; Casanova I; Vázquez E; Mangues R; Villaverde A
    Small; 2018 Jun; 14(26):e1800665. PubMed ID: 29845742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective delivery of T22-PE24-H6 to CXCR4
    Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
    Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
    [No Abstract]   [Full Text] [Related]  

  • 4. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
    Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4
    Sala R; Sánchez-García L; Serna N; Céspedes MV; Casanova I; Roldán M; Sánchez-Chardi A; Unzueta U; Vázquez E; Mangues R; Villaverde A
    Acta Biomater; 2019 Nov; 99():426-432. PubMed ID: 31494293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma.
    Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; León X; Alba-Castellón L; Mangues R
    J Exp Clin Cancer Res; 2022 Feb; 41(1):49. PubMed ID: 35120582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4
    Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I
    Biomed Pharmacother; 2022 Jun; 150():112940. PubMed ID: 35421785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective depletion of metastatic stem cells as therapy for human colorectal cancer.
    Céspedes MV; Unzueta U; Aviñó A; Gallardo A; Álamo P; Sala R; Sánchez-Chardi A; Casanova I; Mangues MA; Lopez-Pousa A; Eritja R; Villaverde A; Vázquez E; Mangues R
    EMBO Mol Med; 2018 Oct; 10(10):. PubMed ID: 30190334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles.
    Serna N; Sánchez JM; Unzueta U; Sánchez-García L; Sánchez-Chardi A; Mangues R; Vázquez E; Villaverde A
    Nanotechnology; 2019 Mar; 30(11):115101. PubMed ID: 30561375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
    Pallarès V; Unzueta U; Falgàs A; Aviñó A; Núñez Y; García-León A; Sánchez-García L; Serna N; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Cedó L; Eritja R; Villaverde A; Vázquez E; Casanova I; Mangues R
    Biomaterials; 2022 Jan; 280():121258. PubMed ID: 34847435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs.
    Sánchez-García L; Serna N; Álamo P; Sala R; Céspedes MV; Roldan M; Sánchez-Chardi A; Unzueta U; Casanova I; Mangues R; Vázquez E; Villaverde A
    J Control Release; 2018 Mar; 274():81-92. PubMed ID: 29408658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models.
    Medina-Gutiérrez E; García-León A; Gallardo A; Álamo P; Alba-Castellón L; Unzueta U; Villaverde A; Vázquez E; Casanova I; Mangues R
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4
    Céspedes MV; Unzueta U; Álamo P; Gallardo A; Sala R; Casanova I; Pavón MA; Mangues MA; Trías M; López-Pousa A; Villaverde A; Vázquez E; Mangues R
    Nanomedicine; 2016 Oct; 12(7):1987-1996. PubMed ID: 27085904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles.
    Unzueta U; Céspedes MV; Ferrer-Miralles N; Casanova I; Cedano J; Corchero JL; Domingo-Espín J; Villaverde A; Mangues R; Vázquez E
    Int J Nanomedicine; 2012; 7():4533-44. PubMed ID: 22923991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.
    Núñez Y; Garcia-León A; Falgàs A; Serna N; Sánchez-García L; Garrido A; Sierra J; Gallardo A; Unzueta U; Vázquez E; Villaverde A; Mangues R; Casanova I
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4
    Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; Mangues R; Alba-Castellón L; León X
    Acta Pharm Sin B; 2022 May; 12(5):2578-2591. PubMed ID: 35646535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases.
    Sala R; Rioja-Blanco E; Serna N; Sánchez-García L; Álamo P; Alba-Castellón L; Casanova I; López-Pousa A; Unzueta U; Céspedes MV; Vázquez E; Villaverde A; Mangues R
    Drug Deliv; 2022 Dec; 29(1):1384-1397. PubMed ID: 35532120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanostructured toxins for the selective destruction of drug-resistant human CXCR4
    Serna N; Álamo P; Ramesh P; Vinokurova D; Sánchez-García L; Unzueta U; Gallardo A; Céspedes MV; Vázquez E; Villaverde A; Mangues R; Medema JP
    J Control Release; 2020 Apr; 320():96-104. PubMed ID: 31931052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles.
    Álamo P; Pallarès V; Céspedes MV; Falgàs A; Sanchez JM; Serna N; Sánchez-García L; Voltà-Duràn E; Morris GA; Sánchez-Chardi A; Casanova I; Mangues R; Vazquez E; Villaverde A; Unzueta U
    Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33105866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines.
    Álamo P; Cedano J; Conchillo-Sole O; Cano-Garrido O; Alba-Castellon L; Serna N; Aviñó A; Carrasco-Diaz LM; Sánchez-Chardi A; Martinez-Torró C; Gallardo A; Cano M; Eritja R; Villaverde A; Mangues R; Vazquez E; Unzueta U
    Acta Biomater; 2021 Aug; 130():211-222. PubMed ID: 34116228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.